Liftstream is an executive search recruitment company in the life sciences sector
PsiOxus Therapeutics Elects Paolo Paoletti as Chairman of the Board
PsiOxus Therapeutics, an immuno-oncology company in Oxford, England, has appointed Paolo Paoletti to Chairman of its Board to replace Michael Moore. Moore will remain on the Board as Deputy Chairman.
Idera Pharmaceuticals Elects Maxine Gowen to Board of Directors
Idera Pharmaceuticals, a clinical-stage biopharmaceutical company developing toll-like receptor and RNA therapeutics for patients with cancer and rare diseases, has appointed Maxine Gowen to its board of directors.
F-star Deepens Scientific Leadership with CSO Hire
F-star, a biopharmaceutical company developing novel bispecific antibodies with a focus on immuno-oncology, has appointed of Dr Neil Brewis as Chief Scientific Officer.
VCs Listening to Pitches for Age-related Diseases
Author: Karl Simpson
Prosensa announces senior management and board appointments
Authored by Karl Simpson
Posted in Executive Appointments, Orphan Drugs and Rare Diseases, Recruitment Market
Tagged Annalisa jenkins, Board of Directors, Chief Commerical Officer, DMD, Duchenne Muscular Dytrophy, Genzyme, GSK, Merck Serono, Prosensa, R&D, research and development, to-BBB, Willem W. van Weperen
Leave a comment
Gene Therapy Start-up AAVLife raises $12m
Authored by James Sheppard
Posted in Orphan Drugs and Rare Diseases, Pharmaceutical business
Tagged AAVLife, Amber Salzman, biotech cluster, Dr Helene Puccio, Dr Pierre Bougneres, Dr Ronald Crystal, France, Friedreich’s Ataxia, funding, gene-deleting therapy, GSK, INSERM, Nature Medicine, Paris, Pierre Aubourg, Versant Ventures
Leave a comment
PTC Therapeutics appoints Chief Medical Officer and communicates CHMP conditional decision
Authored by Karl Simpson
Posted in Orphan Drugs and Rare Diseases, Pharmaceutical business
Tagged Ariad, Ataluren, Chief Medical Officer, CHMP, DMD, Duchenne, Duchenne Muscular Dystrophy, EMA, europe, GSK, Iclusig, investors, MAA, market authorisation application, Murad Husain, oncology, parents, patients, phase III clinical trial, Prosensa, PTC Therapeutics, Rober J. Spiegel, Sarepta, USA, VP Global Regulatory Affairs
Leave a comment
AnaptysBio expands its cancer immunotherapy portfolio
Authored by Karl Simpson
Posted in M&A Finance and Funding, Orphan Drugs and Rare Diseases
Tagged ADCs, AHM-XEL, AnaptysBio, ANB011, anti PD1, Antibodies, Avalon Ventures, cancer, Celltech, Cimzia, David King, fibrosis, GSK, Hamza Suria, immunotherapy, inflammation, LAG-3, Maxygen, oncology, somatic hypermutation, TIM-3, UCB, UK
Leave a comment
Isis gains milestone from GSK for rare disease trial and Aegerion takes them on in HoFH
Authored by Karl Simpson
Posted in Orphan Drugs and Rare Diseases, Pharmaceutical business
Tagged Aegerion, antisense drugs, clinical studies, commercialisation, familial amyloid polyneuropathy, Genzyme, GSK, HoFH, homozygous familial hypercholesterolemia, Isis Pharmaceuticals, ISIS-TTRRX, Kynamro, milestone payments, Orphan drugs, phase 2/3 studies, rare diseases, transthyretin amyloidosis
Leave a comment